FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102238081> ?p ?o ?g. }

• W2102238081 endingPage "46" @default.
• W2102238081 startingPage "40" @default.
• W2102238081 abstract "Background Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. We aimed to assess the efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in adults with this disease. Methods We did a single-arm, open-label, phase 3 study of lomitapide for treatment of patients with homozygous familial hypercholesterolemia. Current lipid lowering therapy was maintained from 6 weeks before baseline through to at least week 26. Lomitapide dose was escalated on the basis of safety and tolerability from 5 mg to a maximum of 60 mg a day. The primary endpoint was mean percent change in levels of LDL cholesterol from baseline to week 26, after which patients remained on lomitapide through to week 78 for safety assessment. Percent change from baseline to week 26 was assessed with a mixed linear model. Findings 29 men and women with homozygous familial hypercholesterolaemia, aged 18 years or older, were recruited from 11 centres in four countries (USA, Canada, South Africa, and Italy). 23 of 29 enrolled patients completed both the efficacy phase (26 weeks) and the full study (78 weeks). The median dose of lomitapide was 40 mg a day. LDL cholesterol was reduced by 50% (95% CI −62 to −39) from baseline (mean 8·7 mmol/L [SD 2·9]) to week 26 (4·3 mmol/L [2·5]; p<0·0001). Levels of LDL cholesterol were lower than 2·6 mmol/L in eight patients at 26 weeks. Concentrations of LDL cholesterol remained reduced by 44% (95% CI −57 to −31; p<0·0001) at week 56 and 38% (–52 to −24; p<0·0001) at week 78. Gastrointestinal symptoms were the most common adverse event. Four patients had aminotransaminase levels of more than five times the upper limit of normal, which resolved after dose reduction or temporary interruption of lomitapide. No patient permanently discontinued treatment because of liver abnormalities. Interpretation Our study suggests that treatment with lomitapide could be a valuable drug in the management of homozygous familial hypercholesterolaemia. Funding FDA Office of the Orphan Product Development, Aegerion Pharmaceuticals." @default.
• W2102238081 created "2016-06-24" @default.
• W2102238081 creator A5003094687 @default.
• W2102238081 creator A5011065242 @default.
• W2102238081 creator A5011536972 @default.
• W2102238081 creator A5012961676 @default.
• W2102238081 creator A5019282494 @default.
• W2102238081 creator A5020434841 @default.
• W2102238081 creator A5029590803 @default.
• W2102238081 creator A5035047137 @default.
• W2102238081 creator A5035358062 @default.
• W2102238081 creator A5035402563 @default.
• W2102238081 creator A5036776701 @default.
• W2102238081 creator A5037375815 @default.
• W2102238081 creator A5056201514 @default.
• W2102238081 creator A5067149045 @default.
• W2102238081 creator A5075555151 @default.
• W2102238081 creator A5078515650 @default.
• W2102238081 creator A5090781778 @default.
• W2102238081 date "2013-01-01" @default.
• W2102238081 modified "2023-10-14" @default.
• W2102238081 title "Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study" @default.
• W2102238081 cites W10351664 @default.
• W2102238081 cites W1968949098 @default.
• W2102238081 cites W1976195699 @default.
• W2102238081 cites W1987451368 @default.
• W2102238081 cites W1991671549 @default.
• W2102238081 cites W1992969017 @default.
• W2102238081 cites W2026205222 @default.
• W2102238081 cites W2029789115 @default.
• W2102238081 cites W2036394293 @default.
• W2102238081 cites W2046141067 @default.
• W2102238081 cites W2046959088 @default.
• W2102238081 cites W2066398399 @default.
• W2102238081 cites W2079699385 @default.
• W2102238081 cites W2082911286 @default.
• W2102238081 cites W2090130007 @default.
• W2102238081 cites W2142526970 @default.
• W2102238081 cites W2152726242 @default.
• W2102238081 cites W2158507234 @default.
• W2102238081 cites W2166390550 @default.
• W2102238081 cites W2168876694 @default.
• W2102238081 cites W4243500197 @default.
• W2102238081 cites W4255876143 @default.
• W2102238081 doi "https://doi.org/10.1016/s0140-6736(12)61731-0" @default.
• W2102238081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4587657" @default.
• W2102238081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23122768" @default.
• W2102238081 hasPublicationYear "2013" @default.
• W2102238081 type Work @default.
• W2102238081 sameAs 2102238081 @default.
• W2102238081 citedByCount "590" @default.
• W2102238081 countsByYear W21022380812012 @default.
• W2102238081 countsByYear W21022380812013 @default.
• W2102238081 countsByYear W21022380812014 @default.
• W2102238081 countsByYear W21022380812015 @default.
• W2102238081 countsByYear W21022380812016 @default.
• W2102238081 countsByYear W21022380812017 @default.
• W2102238081 countsByYear W21022380812018 @default.
• W2102238081 countsByYear W21022380812019 @default.
• W2102238081 countsByYear W21022380812020 @default.
• W2102238081 countsByYear W21022380812021 @default.
• W2102238081 countsByYear W21022380812022 @default.
• W2102238081 countsByYear W21022380812023 @default.
• W2102238081 crossrefType "journal-article" @default.
• W2102238081 hasAuthorship W2102238081A5003094687 @default.
• W2102238081 hasAuthorship W2102238081A5011065242 @default.
• W2102238081 hasAuthorship W2102238081A5011536972 @default.
• W2102238081 hasAuthorship W2102238081A5012961676 @default.
• W2102238081 hasAuthorship W2102238081A5019282494 @default.
• W2102238081 hasAuthorship W2102238081A5020434841 @default.
• W2102238081 hasAuthorship W2102238081A5029590803 @default.
• W2102238081 hasAuthorship W2102238081A5035047137 @default.
• W2102238081 hasAuthorship W2102238081A5035358062 @default.
• W2102238081 hasAuthorship W2102238081A5035402563 @default.
• W2102238081 hasAuthorship W2102238081A5036776701 @default.
• W2102238081 hasAuthorship W2102238081A5037375815 @default.
• W2102238081 hasAuthorship W2102238081A5056201514 @default.
• W2102238081 hasAuthorship W2102238081A5067149045 @default.
• W2102238081 hasAuthorship W2102238081A5075555151 @default.
• W2102238081 hasAuthorship W2102238081A5078515650 @default.
• W2102238081 hasAuthorship W2102238081A5090781778 @default.
• W2102238081 hasBestOaLocation W21022380812 @default.
• W2102238081 hasConcept C126322002 @default.
• W2102238081 hasConcept C13028836 @default.
• W2102238081 hasConcept C134018914 @default.
• W2102238081 hasConcept C197934379 @default.
• W2102238081 hasConcept C203092338 @default.
• W2102238081 hasConcept C2778163477 @default.
• W2102238081 hasConcept C2778375690 @default.
• W2102238081 hasConcept C2778913445 @default.
• W2102238081 hasConcept C2779120738 @default.
• W2102238081 hasConcept C2780072125 @default.
• W2102238081 hasConcept C535046627 @default.
• W2102238081 hasConcept C71924100 @default.
• W2102238081 hasConcept C8243546 @default.
• W2102238081 hasConcept C90924648 @default.
• W2102238081 hasConceptScore W2102238081C126322002 @default.
• W2102238081 hasConceptScore W2102238081C13028836 @default.

• next